Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2016-10-16 Capital/Financing Update
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Opthea receives $2.6M R&D tax incentive 3 pages 58.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX and media release dated October 17, 2016, announcing that Opthea Limited has received a $2.6 million R&D tax incentive refund for the financial year ended June 30, 2016. The content focuses on the receipt of the tax incentive, details about the company's R&D activities, and background information about the company and its lead drug candidate. There are no financial statements, detailed financial performance data, or comprehensive management discussion and analysis. The document is a corporate announcement about a financing-related event (receipt of a government R&D tax refund), which is a capital/financing update rather than a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the refund and its impact. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-10-16 English
Appendix 3B 13 pages 160.0KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, issue price, terms, and compliance with ASX rules. It includes sections on quotation of securities, calculation of placement capacity under ASX rules, and warranties to ASX. The document is a formal announcement related to a new share issue and application for quotation of additional securities on the Australian Securities Exchange (ASX). It is not a financial report, earnings release, or management discussion, but a regulatory announcement about capital raising and securities issuance. This matches the definition of a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the announcement itself, not just a brief notice or report publication announcement.
2016-10-09 English
Opthea Ph1 wAMD data presented at EURETINA 2016 3 pages 260.3KB
Investor Presentation Classification · 95% confidence The document is a press release announcing the presentation of Phase 1 clinical trial data at a medical congress (EURETINA Congress 2016). It describes the clinical trial, the drug under development, and the presentation event, but does not contain any financial statements, regulatory filings, or detailed financial or management reports. It is not an earnings release, annual report, or interim report. It is also not a regulatory filing or certification. The document is primarily an announcement of clinical trial data presentation to investors and the public, which aligns best with an Investor Presentation (IP) category, as it focuses on scientific and clinical data relevant to investors and stakeholders. The document length (8966 characters) and content support this classification rather than a short announcement or a full report.
2016-09-11 English
Appendix 4E and Annual Report 2016 82 pages 7.2MB
Annual Report Classification · 95% confidence The document is an ASX announcement dated 29 August 2016, titled 'Appendix 4E Preliminary final report' for the year ended 30 June 2016. It includes detailed financial results, a Chairman and CEO overview, Directors' Report, and extensive financial statements such as Consolidated Statement of Profit and Loss, Statement of Financial Position, and Auditor's Report. The content covers the full annual performance and business overview of Opthea Limited for the fiscal year 2015-2016. The length is substantial (15,000 characters) and contains actual financial data and analysis, not just an announcement or summary. This matches the characteristics of an Annual Report (10-K equivalent) rather than a brief earnings release or announcement. Therefore, the document should be classified as an Annual Report (10-K).
2016-08-28 English
Appendix 4G and Corporate Governance Statement 2016 19 pages 200.1KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which pertain to corporate governance disclosures that must accompany the annual report. It includes a detailed key to disclosures against the ASX Corporate Governance Council Principles and Recommendations for the financial year ended 30 June 2016. The document is a governance statement or a compliance checklist related to corporate governance practices, referencing the corporate governance statement either in the annual report or on the company's website. It does not contain financial statements or management discussion of financial results but focuses on governance practices and compliance with governance recommendations. This aligns with the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document is substantive (15,000 characters) and not merely an announcement or certification. Therefore, the appropriate classification is CGR with high confidence.
2016-08-28 English
Opthea to Present at Ophthalmology Innovation Summit in US 3 pages 309.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 8 August 2016 from Opthea Limited announcing that the CEO will present at the Ophthalmology Innovation Summit. The content focuses on the presentation of clinical trial data for a drug candidate (OPT-302) and provides background on the company, the disease, and the drug. It also includes forward-looking statements and investment risk disclosures. There are no financial statements, detailed financial analysis, or regulatory filings such as annual or interim reports. The document is a public announcement about a presentation event and related information, not a report or transcript. It is longer than 5,000 characters but does not contain substantive financial data or detailed report content. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and media release that does not fit other specific categories.
2016-08-07 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.